急性脑梗死治疗中尤瑞克林联合依达拉奉的应用效果

Application of Urinary Kallidinogenase Combined with Edaravone in the Treatment of Acute Cerebral Infarction

目的 针对急性脑梗死患者实施尤瑞克林联合依达拉奉作为治疗方案,进一步探究临床治疗的成效。方法 选取2019年1月至2019年12月收治的急性脑梗死患者作为研究的对象。通过回顾性分析进行研究,将90例患者采用随机数表法分组,以公平性开展为前提进行分组调查。对照组患者采用常规基础上应用依达拉奉,观察组则为尤瑞克林联合依达拉奉,分析治疗成效。结果 从治疗质量上看,观察组患者治疗后的神经功能缺损(NIHSS)评分为(9.64±3.52)分,对照组为(15.33±7.61)分,此外,在Barthel生活指数对比中,观察组治疗后为(72.56±4.32)分,对照组则为(52.21±4.12)分,组间对比差异有统计学意义(P <0.05)。与此同时针对肿瘤坏死因子-α、超敏C反应蛋白指标进行调研,治疗后,观察组患者分别为(7.88±2.54)μg/L和(9.57±2.12)mg/L,明显优于对照组的(11.31±3.58)μg/L和(16.25±2.63)mg/L,差异有统计学意义(P <0.05)。治疗后,观察组患者降钙素原(0.56±0.12)ng/m L优于对照组(0.76±0.14)ng/m L,差异有统计学意义(P <0.05)。收集被氧化的低密度脂蛋白数据,观察组患者治疗后为(99.15±6.25)μg/L,对照组则为(115.96±81.14)μg/L,差异有统计学意义(P <0.05)。结论 采用尤瑞克林联合依达拉奉治疗急性脑梗死效果显著,能够改善患者的神经功能缺损情况,并有助于提升药效的协同作用,降低机体炎性反应,患者治疗反馈良好。

Objective To investigate the effect of clinical treatment of acute cerebral infarction patients with ureclin combined with edaravone.Methods Acute cerebral infarction patients admitted from January 2019 to December 2019 were selected as the study objects. Through retrospective analysis, 90 patients were randomly divided into groups and investigated on the premise of fairness. The patients in the control group were treated with edaravone on the basis of routine treatment, while those in the observation group were treated with ureclin and edaravone. Results The NIHSS score of patients with neurological deficit after treatment in the observation group was(9.64±3.52) and that of the control group was(15.33±7.61), in addition, in the Barthel life index comparison, the observation group was(72.56±4.32) after treatment, and the control group was(52.21±4.12), and the difference between the groups was significant and statistically significant(P<0.05). At the same time, we also investigated the tumor necrosis factor-α and hypersensitive C-reactive protein. After treatment, the patients in the observation group were(7.88±2.54) μg/L and(9.57±2.12) mg/L, respectively, which were significantly better than those in the control group(11.31±3.58) μg/L and(16.25±2.63) mg/L, the difference was statistically significant(P<0.05).After treatment, calcitoninogen(0.56 ± 0.12) ng/mL was better in the observation group than in the control group(0.76±0.14) ng/mL, and the difference was statistically significant(P<0.05). In addition, we also collected the data of oxidized LDL, the patients in the observation group were(99.15±6.25) μg/L after treatment, while the patients in the control group were(115.96±81.14) μg/L, the difference was statistically significant(P<0.05). Conclusion The combination of urinary kallidinogenase and edaravone is effective in the treatment of acute cerebral infarction, which can improve the neurological deficit of patients, enhance the synergistic effect of drug efficacy, reduce the inflammatory response of the body, and the patients have good treatment feedback.